Recent drug approvals in the field of prostate cancer therapy have brought about a change in the treatment landscape of locally advanced and metastatic castration-resistant prostate cancer. While this improvement offers a welcoming change in the standard treatment practice of prostate cancer, questions remain with regard to the proper sequencing of the right therapy for the appropriate patient. This review highlights the pre-clinical, safety and clinical studies that help bring to the forefront the drugs recently approved for the treatment of advanced prostate cancer and offer some insights to its use.PublishedN/
Despite many recent advances in the therapy for metastatic castration-resistant prostate cancer (mCR...
Novel drugs, drug sequences and combinations have improved the outcome of prostate cancer in recent ...
Advanced prostate cancer includes a wide spectrum of disease ranging from hormone naïve or hormone s...
This review examines the development and efficacy of novel treatment options for advanced prostate c...
The past few years have brought increasing advances in the therapeutic management of metastatic cast...
Prostate cancer is the most common cancer amongst men in the USA and the second most common malignan...
The treatment landscape for advanced prostate cancer is evolving rapidly, with new agents and strate...
OBJECTIVES: To examine the current literature and identify key consensus findings from the available...
The effective treatment of castrate-resistant prostate cancer (CRPC) has proven to be very challengi...
Androgen deprivation therapy has become the mainstay of the treatment of advanced prostate cancer, b...
The effective treatment of castrate-resistant prostate cancer (CRPC) has proven to be very challengi...
The management of advanced prostate cancer has evolved rapidly. Androgen deprivation therapy, throug...
Prostate cancer being the second most frequent and fifth leading cause of mortality has led to condu...
CONTEXT: Until recently, the only approved agent for metastatic castration-resistant prostate cancer...
The treatment of advanced prostate cancer has evolved due to recent advances in molecular research a...
Despite many recent advances in the therapy for metastatic castration-resistant prostate cancer (mCR...
Novel drugs, drug sequences and combinations have improved the outcome of prostate cancer in recent ...
Advanced prostate cancer includes a wide spectrum of disease ranging from hormone naïve or hormone s...
This review examines the development and efficacy of novel treatment options for advanced prostate c...
The past few years have brought increasing advances in the therapeutic management of metastatic cast...
Prostate cancer is the most common cancer amongst men in the USA and the second most common malignan...
The treatment landscape for advanced prostate cancer is evolving rapidly, with new agents and strate...
OBJECTIVES: To examine the current literature and identify key consensus findings from the available...
The effective treatment of castrate-resistant prostate cancer (CRPC) has proven to be very challengi...
Androgen deprivation therapy has become the mainstay of the treatment of advanced prostate cancer, b...
The effective treatment of castrate-resistant prostate cancer (CRPC) has proven to be very challengi...
The management of advanced prostate cancer has evolved rapidly. Androgen deprivation therapy, throug...
Prostate cancer being the second most frequent and fifth leading cause of mortality has led to condu...
CONTEXT: Until recently, the only approved agent for metastatic castration-resistant prostate cancer...
The treatment of advanced prostate cancer has evolved due to recent advances in molecular research a...
Despite many recent advances in the therapy for metastatic castration-resistant prostate cancer (mCR...
Novel drugs, drug sequences and combinations have improved the outcome of prostate cancer in recent ...
Advanced prostate cancer includes a wide spectrum of disease ranging from hormone naïve or hormone s...